Refine by
Patient Survival Articles & Analysis
65 news found
” ORSERDU is approved under the FDA’s Priority Review and Fast Track designation based on the results of the registrational Phase III trial EMERALD, that demonstrated statistically significant progression-free survival (PFS) with elacestrant vs SOC endocrine monotherapy (fulvestrant, letrozole, anastrozole, exemestane), meeting both primary endpoints in all ...
Patients in the study were randomized to receive either elacestrant or the investigator’s choice of an approved hormonal agent. The primary endpoints of the study were progression-free survival (PFS) in the overall patient population and in patients with estrogen receptor 1 gene (ESR1) mutations. Secondary endpoints ...
The primary focus of the TIGeR-PaC study is to administer targeted therapy to pancreatic cancer patients safely and without transmission to non-targeted areas. The end goals are to determine whether this targeted method of delivering chemotherapy can extend survival while also improving quality of life. ...
ByxCures
Non-responders had lower DS and survival than patients with high DS. Conclusions from the study suggest that DS-low MDS patients should be considered for novel combination therapy at the time of diagnosis. ...
The study also found inferior overall survival (OS) for MRD compared to the historical experience of unmethylated-MGMT patients, suggesting that TMZ-induced hypermutation may compromise survival. ...
The combination therapy demonstrated an ORR of 52.4% (based on all treated patients) regardless of PD-L1 status. The results are based on early data from 21 patients, including 10 patients who reached partial response (PR) and 1 patient who achieved a complete response (CR). ...
” Significant mitral regurgitation prevalence rates are estimated to be up to 10% to 25% in patients in their seventies. During the procedure, operators implant one or more clips onto the valve leaflets with real-time echocardiographic imaging. Clinical data suggests MitraClip helps improve symptoms and survival in appropriately selected ...
Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML). Clinical activity observed includes continuing robust durability of relapse-free survival; all three patients in Cohort 1 remain alive and progression-free; ongoing durations of response exceed 12 ...
Miller and Marshall Pitz, describe the activity of LNP-siSAT1 against the GB cells and its ability to further sensitized them towards radiation and chemotherapy providing an avenue to increase treatment efficacy and hence potentially increase survival. The outcome of the study will dramatically impact therapeutic intervention associated with this lethal cancer. ...
ITM is developing ITM-11 to provide patients with a new, targeted treatment approach to these difficult-to-treat tumors with the goal to improve clinical outcome and quality of life. ...
There remains an unmet need to extend survival for patients with these life-threatening diseases and XPOVIO® presents Taiwan physicians and patients with a new novel addition to existing therapies. ...
“Combining trifluridine/tipiracil with bevacizumab demonstrated the potential to extend survival in these patients who have limited therapeutic options.” Fabio Benedetti, M.D., Global Chief Medical Officer for Oncology at Taiho Pharmaceutical said: “Trifluridine/tipiracil – discovered by Taiho and developed in our partnership with Servier ...
Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival? SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating ...
“There’s a clear unmet need for earlier and more accurate cancer diagnostics and INOVIQ is developing a multi-product diagnostics pipeline for different cancers and test purposes to improve patient outcomes and survival,” she said. “Our diagnostics pipeline currently includes SubB2M-based tests in development for monitoring breast and ...
Andrej Babic, Chief Executive Officer and co-founder at Adiposs SA said: “Brown fat plays a central role in human metabolism and has a big impact on the prognosis and survival of cancer patients. However, there are no approved products to detect brown fat in patients today. ...
ByAdiposs
“Darolutamide plus ADT and docetaxel has shown significant benefit in overall survival and a favorable safety profile for patients with metastatic hormone-sensitive prostate cancer,” said Matthew Smith, M.D., Ph.D., Director of the Genitourinary Malignancies Program, Massachusetts General Hospital Cancer Center. “This new indication for ...
ByBayer AG
Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research Reports Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic ...
FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated approval application Q4 2022: Expected initiation of randomized, controlled ...
The next step is to evaluate whether biosimulation-informed therapy selection can be used prospectively to improve the survival of GEA patients.” “Gaining a better understanding of the molecular determinants of gastroesophageal adenocarcinoma is key to improving therapy response rates for GEA patients,” Dr. ...
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-024-04 study, which demonstrate that the Cellworks SingulaTM Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) and Progression-Free Survival (PFS) for newly diagnosed ...